Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (461-470 of 505) with videos related to

Pageof 51
Sort By:
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR ExpressionHeather J Dalton, Sunila Pradeep, Michael McGuire, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
International Journal of Molecular Sciences|October 13, 2021
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic SyndromePetra Gorombei, Fabien Guidez, Saravanan Ganesan, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaKiyomi Morita, Hagop M Kantarjian, Feng Wang, et al.
Journal of Hematology & Oncology|October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLMusa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Journal of Hematology & Oncology|February 23, 2021
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLMusa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Pageof 51

Showing results (461-470 of 505) with videos related to

Sort By:
Pageof 51
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR ExpressionHeather J Dalton, Sunila Pradeep, Michael McGuire, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
International Journal of Molecular Sciences|October 13, 2021
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic SyndromePetra Gorombei, Fabien Guidez, Saravanan Ganesan, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaKiyomi Morita, Hagop M Kantarjian, Feng Wang, et al.
Journal of Hematology & Oncology|October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLMusa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Journal of Hematology & Oncology|February 23, 2021
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLMusa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Pageof 51